0001608390--12-312022Q2錯誤2022-06-3000016083902021-01-012021-06-3000016083902022-01-012022-06-300001608390FMDD:運輸我的成員2022-01-012022-06-300001608390FMD:運輸成員2022-01-012022-06-300001608390FMD:運輸成員2022-01-012022-06-300001608390Afmd:ShareBasedPaymentWithServiceConditionMember2022-06-300001608390Afmd:ShareBasedPaymentWithMarketConditionsMember2022-06-300001608390Afmd:ShareBasedPaymentWithServiceConditionMember2021-06-300001608390IFRS-FULL:底部範圍成員Afmd:esop2014成員2022-04-012022-06-300001608390IFRS-Full:TopOfRangeMemberAfmd:esop2014成員2022-01-012022-06-300001608390IFRS-Full:不晚於一年成員2022-06-300001608390IFRS-Full:晚於一年成員2022-06-300001608390FMDD:RoivantScience有限公司成員2021-01-012021-12-310001608390Afmd:GenentechIncMember2021-01-012021-12-310001608390FMDD:RoivantScience有限公司成員2022-04-012022-06-300001608390Afmd:GenentechIncMember2022-04-012022-06-300001608390FMDD:RoivantScience有限公司成員2022-01-012022-06-300001608390Afmd:GenentechIncMember2022-01-012022-06-300001608390FMDD:RoivantScience有限公司成員2021-04-012021-06-300001608390Afmd:GenentechIncMember2021-04-012021-06-300001608390FMDD:RoivantScience有限公司成員2021-01-012021-06-300001608390Afmd:GenentechIncMember2021-01-012021-06-300001608390Ifrs-full:GoodsOrServicesTransferredOverTimeMember2022-04-012022-06-300001608390Ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2022-04-012022-06-300001608390國家:美國2022-04-012022-06-300001608390國家:德2022-04-012022-06-300001608390Afmd:服務成員2022-04-012022-06-300001608390Afmd:協作服務成員2022-04-012022-06-300001608390Ifrs-full:GoodsOrServicesTransferredOverTimeMember2022-01-012022-06-300001608390Ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2022-01-012022-06-300001608390國家:美國2022-01-012022-06-300001608390國家:德2022-01-012022-06-300001608390Afmd:服務成員2022-01-012022-06-300001608390Afmd:協作服務成員2022-01-012022-06-300001608390Ifrs-full:GoodsOrServicesTransferredOverTimeMember2021-04-012021-06-300001608390Ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2021-04-012021-06-300001608390國家:美國2021-04-012021-06-300001608390國家:德2021-04-012021-06-300001608390Afmd:服務成員2021-04-012021-06-300001608390Afmd:協作服務成員2021-04-012021-06-300001608390Ifrs-full:GoodsOrServicesTransferredOverTimeMember2021-01-012021-06-300001608390Ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember2021-01-012021-06-300001608390國家:美國2021-01-012021-06-300001608390國家:德2021-01-012021-06-300001608390Afmd:服務成員2021-01-012021-06-300001608390Afmd:協作服務成員2021-01-012021-06-300001608390Afmd:LoanAgreementWithUniCreditLeasingCZMember2019-04-012019-06-300001608390IFRS-Full:RetainedEarningsMembers2021-01-012021-06-300001608390Afmd:LoanFacilityTranchetTwoMemberIfrs-full:EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember2021-12-012021-12-310001608390Afmd:LoanFacilityTrancheOneMembersIfrs-full:EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember2021-02-012021-02-280001608390IFRS-FULL:重新評估盈餘成員2021-01-012021-06-300001608390AFMD:CommonSharesRoivantScience Ltd.成員2022-08-050001608390Afmd:SharesIssuedInPublicOfferingMember2022-04-180001608390Afmd:SharesIssuedInPublicOfferingAndOverAllotmentOptionMember2022-04-180001608390Afmd:esop2014成員2022-06-300001608390Afmd:esop2014成員2021-12-310001608390Afmd:esop2014成員2021-01-012021-12-310001608390Ifrs-full:EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMemberIFRS-Full:TopOfRangeMember2021-01-310001608390Afmd:LoanFacilityTranchetTwoMemberIfrs-full:EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember2021-01-310001608390Afmd:LoanFacilityTranscheThreeMemberIfrs-full:EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember2021-01-310001608390Afmd:LoanFacilityTrancheOneMembersIfrs-full:EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember2021-01-310001608390IFRS-Full:IssuedCapitalMembers2022-01-012022-06-300001608390IFRS-Full:CapitalReserve成員2022-01-012022-06-300001608390IFRS-Full:IssuedCapitalMembers2021-01-012021-06-300001608390IFRS-Full:CapitalReserve成員2021-01-012021-06-300001608390Ifrs-full:EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember2022-06-300001608390Afmd:其他財務收入財務成本成員2022-04-012022-06-300001608390Afmd:InterestSVBLoanAgreement成員2022-04-012022-06-300001608390Afmd:外匯兑換差異成員2022-04-012022-06-300001608390Afmd:其他財務收入財務成本成員2022-01-012022-06-300001608390Afmd:InterestSVBLoanAgreement成員2022-01-012022-06-300001608390Afmd:外匯兑換差異成員2022-01-012022-06-300001608390Afmd:其他財務收入財務成本成員2021-04-012021-06-300001608390Afmd:InterestSVBLoanAgreement成員2021-04-012021-06-300001608390Afmd:外匯兑換差異成員2021-04-012021-06-300001608390Afmd:其他財務收入財務成本成員2021-01-012021-06-300001608390Afmd:InterestSVBLoanAgreement成員2021-01-012021-06-300001608390Afmd:外匯兑換差異成員2021-01-012021-06-300001608390IFRS-FULL:非當前資產HeldForSaleMemberAFMD:CommonSharesRoivantScience Ltd.成員2022-06-300001608390AFMD:CommonSharesRoivantScience Ltd.成員2021-12-310001608390Afmd:研究和開發成員2022-04-012022-06-300001608390Afmd:一般成員和管理成員2022-04-012022-06-300001608390Afmd:研究和開發成員2022-01-012022-06-300001608390Afmd:一般成員和管理成員2022-01-012022-06-300001608390Afmd:研究和開發成員2021-04-012021-06-300001608390Afmd:一般成員和管理成員2021-04-012021-06-300001608390Afmd:研究和開發成員2021-01-012021-06-300001608390Afmd:一般成員和管理成員2021-01-012021-06-300001608390IFRS-Full:TopOfRangeMemberAfmd:esop2014成員2022-06-300001608390IFRS-FULL:底部範圍成員Afmd:esop2014成員2022-06-300001608390IFRS-FULL:重新評估盈餘成員2022-06-300001608390IFRS-Full:RetainedEarningsMembers2022-06-300001608390IFRS-Full:IssuedCapitalMembers2022-06-300001608390IFRS-Full:CapitalReserve成員2022-06-300001608390IFRS-FULL:重新評估盈餘成員2021-12-310001608390IFRS-Full:RetainedEarningsMembers2021-12-310001608390IFRS-Full:IssuedCapitalMembers2021-12-310001608390IFRS-Full:CapitalReserve成員2021-12-310001608390IFRS-FULL:重新評估盈餘成員2021-06-300001608390IFRS-Full:RetainedEarningsMembers2021-06-300001608390IFRS-Full:IssuedCapitalMembers2021-06-300001608390IFRS-Full:CapitalReserve成員2021-06-300001608390IFRS-FULL:重新評估盈餘成員2020-12-310001608390IFRS-Full:RetainedEarningsMembers2020-12-310001608390IFRS-Full:IssuedCapitalMembers2020-12-310001608390IFRS-Full:CapitalReserve成員2020-12-310001608390Afmd:ShareBasedPaymentWithServiceConditionMember2022-01-012022-06-300001608390Afmd:ShareBasedPaymentWithMarketConditionsMember2022-01-012022-06-300001608390Afmd:ShareBasedPaymentWithServiceConditionMember2021-01-012021-06-300001608390Afmd:AmendmentsToIas8AccountingPoliciesChangesInAccountingEstimatesAndErrorsDefinitionOfAccountingEstimatesMember2022-01-012022-06-300001608390Afmd:AmendmentsToIas1PresentationOfFinancialStatementsClassificationOfLiabilitiesAsCurrentOrNonCurrentMember2022-01-012022-06-300001608390Afmd:AmendmentsToIas1PresentationOfFinancialStatementsAndIfrsPracticeStatement2DisclosureOfAccountingPoliciesMember2022-01-012022-06-300001608390Afmd:AmendmentsToIas12IncomeTaxesDeferredTaxRelatedToAssetsAndLiabilitiesArisingFromSingleTransactionMember2022-01-012022-06-3000016083902021-06-3000016083902020-12-310001608390IFRS-FULL:底部範圍成員AFMD:OneMonthEURIBORMembers2021-01-310001608390IFRS-Full:TopOfRangeMember2021-01-310001608390Afmd:LoanAgreementWithUniCreditLeasingCZMember2022-06-300001608390Afmd:LoanAgreementWithUniCreditLeasingCZMember2021-12-3100016083902021-04-012021-06-300001608390Afmd:SharesIssuedUnderNewAtMarketProgramMember2021-11-012021-11-300001608390IFRS-FULL:重新評估盈餘成員2022-01-012022-06-300001608390IFRS-Full:RetainedEarningsMembers2022-01-012022-06-300001608390Afmd:GenentechIncMember2022-06-300001608390FMDD:RoivantScience有限公司成員2020-11-090001608390Afmd:SharesIssuedInPublicOfferingMember2022-04-182022-04-180001608390Fmd:UtakemmerichKellMembers2022-06-300001608390Afmd:UlrichGrauMember2022-06-300001608390Afmd:託馬斯赫克成員2022-06-300001608390最新消息:MathieuSimonMember2022-06-300001608390FMD:HarryWeltenMembers2022-06-300001608390Afmd:FerdinandVerdonck Members2022-06-300001608390記者:伯恩哈德·埃默爾成員2022-06-300001608390Afmd:Annalisa Jenkins成員2022-06-300001608390Afmd:AdiHoessMember2022-06-300001608390Fmd:UtakemmerichKellMembers2021-12-310001608390Afmd:UlrichGrauMember2021-12-310001608390Afmd:託馬斯赫克成員2021-12-310001608390最新消息:MathieuSimonMember2021-12-310001608390FMD:HarryWeltenMembers2021-12-310001608390Afmd:FerdinandVerdonck Members2021-12-310001608390記者:伯恩哈德·埃默爾成員2021-12-310001608390Afmd:Annalisa Jenkins成員2021-12-310001608390Afmd:AdiHoessMember2021-12-310001608390AFMD:CommonSharesRoivantScience Ltd.成員2022-07-012022-08-050001608390Afmd:硅谷銀行貸款成員2022-01-012022-06-3000016083902022-04-012022-06-300001608390Afmd:監事會成員2022-04-012022-06-300001608390Afmd:管理董事會董事成員2022-04-012022-06-300001608390Afmd:監事會成員2022-01-012022-06-300001608390Afmd:管理董事會董事成員2022-01-012022-06-300001608390Afmd:監事會成員2021-04-012021-06-300001608390Afmd:管理董事會董事成員2021-04-012021-06-300001608390Afmd:監事會成員2021-01-012021-06-300001608390Afmd:管理董事會董事成員2021-01-012021-06-300001608390Afmd:esop2014成員2022-04-012022-06-300001608390IFRS-Full:首選項共享成員2022-06-300001608390IFRS-Full:首選項共享成員2021-12-310001608390Afmd:esop2014成員2022-01-012022-06-300001608390Afmd:LoanAgreementWithUniCreditLeasingCZMember2019-04-3000016083902022-06-3000016083902021-12-310001608390Afmd:GenentechIncMember2018-10-012018-10-310001608390FMDD:RoivantScience有限公司成員2020-11-092020-11-090001608390AFMD:CommonSharesRoivantScience Ltd.成員2022-04-012022-06-30ISO4217:歐元ISO4217:歐元Xbrli:共享ISO 4217:美元Xbrli:共享ISO 4217:美元Xbrli:共享聯邦住房金融局:部分Xbrli:純Afmd:是Afmd:EquityInstruments

美國

美國證券交易委員會

華盛頓特區,20549

表格6-K

國外私人發行商報告

根據規則第13a-16或15d-16

1934年《證券交易法》

2022年8月

委託文件編號:001-36619

已確認的N.V.

我是Neuenheimer Feld 582,

海德堡69120號

德國

(主要執行辦公室地址)

用複選標記表示註冊人是否在20-F表或40-F表的封面下提交或將提交年度報告

 Form 20-F  表格40-F

用複選標記表示註冊人是否按照S-T規則101(B)(1)所允許的紙質形式提交了表格6-K:

用複選標記表示註冊人是否按照S-T規則101(B)(7)所允許的紙質形式提交表格6-K:

以引用方式成立為法團

本報告中表格6-K的證物99.1和99.2應被視為已通過引用納入Affimed N.V.表格F-3(註冊號333-251658)、表格F-3(註冊號333-260946)和表格S-8(註冊號333-198812)的註冊聲明中,並自本報告提交之日起成為其中的一部分,但不得被隨後提交或提交的文件或報告所取代。

本報告的表6-K中的附件99.3不應被視為就1934年《證券交易法》(下稱《交易法》)第18條的目的而提交或以其他方式承擔該條的責任,也不應被視為通過引用被納入根據1933年《證券法》或《交易法》提交的任何文件。

簽名

根據1934年《證券交易法》的要求,註冊人已於2022年8月11日在德國海德堡正式授權以下籤署人代表註冊人簽署本報告。

AFFIMED N.V.

發信人:

/s/阿迪·霍斯

姓名:

阿迪·霍斯

標題:

首席執行官

發信人:

/s/安格斯·史密斯

姓名:

安格斯·史密斯

標題:

首席財務官

展品索引

展品

    

展品説明

99.1

截至2022年6月30日的未經審計簡明綜合中期財務報表。

99.2

肯定N.V.管理層對財務狀況和經營結果的討論和分析。

99.3

Apimed N.V.日期為2022年8月11日的新聞稿。

101.INS

XBRL實例文檔。

101.SCH

XBRL分類擴展架構文檔。

101.CAL

XBRL分類擴展計算鏈接庫文檔。

101.DEF

XBRL分類擴展定義Linkbase文檔。

101.IAB

XBRL分類擴展標籤Linkbase文檔。

101.PRE

XBRL分類擴展演示文稿Linkbase文檔。

104

封面交互數據文件(嵌入在內聯XBRL文檔中)。